RPRX (Royalty Pharma) Current Accrued Expense: $108 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPRX Royalty Pharma PLC RPRX
73 GF Score
Price $58.61
GF Value $33.47
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Royalty Pharma Current Accrued Expense?

Royalty Pharma RPRX +0.07% 73 Current Accrued Expense is $108 Mil as of Jun. 2026. GuruFocus rates RPRX with a GF Score™ of 73/100 and a GF Value™ of $33.47 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Royalty Pharma's Current Accrued Expense for the quarter that ended in Jun. 2026 was $108 Mil.

Royalty Pharma's quarterly Current Accrued Expense declined from Dec. 2025 ($111 Mil) to Mar. 2026 ($25 Mil) but then increased from Mar. 2026 ($25 Mil) to Jun. 2026 ($108 Mil).

Royalty Pharma's annual Current Accrued Expense increased from Dec. 2023 ($52 Mil) to Dec. 2024 ($98 Mil) and increased from Dec. 2024 ($98 Mil) to Dec. 2025 ($111 Mil).

Royalty Pharma Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Current Accrued Expense Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only 57.70 54.16 51.68 98.06 110.82

Royalty Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 85.61 29.04 110.82 25.30 107.77
RPRX
73GF Score
Royalty Pharma PLC RPRX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $108 Mil mean?
Royalty Pharma (RPRX) has a Current Accrued Expense of $108 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Current Accrued Expense too high?
Royalty Pharma's current Current Accrued Expense is $108 Mil. Overall, Royalty Pharma has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Current Accrued Expense compare to ROIV and INCY?
Royalty Pharma's Current Accrued Expense of $108 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Current Accrued Expense is $108 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (RPRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $33.47, compared to a current price of $58.61 — trading 75.1% above its estimated fair value. The current Current Accrued Expense is $108 Mil. Royalty Pharma's overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Royalty Pharma (RPRX), the current Current Accrued Expense is $108 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (RPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of $58.61 is trading 75.1% above its estimated GF Value™ of $33.47. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for RPRX:

  • Current Accrued Expense: $108 Mil
  • GF Value™: $33.47 vs. price of $58.61 (75.1% above fair value)
  • GF Score™: 73/100 with 9 warning signs

No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
73GF Score

Get the complete analysis for RPRX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.61
Price
$33.47
GF Value